Asceneuron secures $100 million oversubscribed Series C financing
Led by Novo Holdings, with new investment from EQT Life Sciences, OrbiMed and SR One. Funds will advance ASN51 into Phase 2 trials for Alzheimer's disease.
See the latest news and media coverage for Asceneuron. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing treatments for neurodegenerative diseases
asceneuron.comLast updated
In short: Asceneuron halted an Alzheimer's trial amid tau-targeting setbacks after raising $100 million to advance ASN51.
Led by Novo Holdings, with new investment from EQT Life Sciences, OrbiMed and SR One. Funds will advance ASN51 into Phase 2 trials for Alzheimer's disease.
It will contribute its OGA inhibitor expertise to advance biomarkers such as tau PET and help accelerate new Alzheimer's therapies.
He brings over 35 years in healthcare, having led global pharmaceuticals at GSK and served as Vifor Pharma's CEO, succeeding Peter Van Vlasselaer.
Angehrn Pavik brings over 20 years of experience at Amgen, Onyx, Exelixis and Vifor. Outgoing CEO Dirk Beher becomes Chief Scientific Advisor as two compounds advance in clinical development.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s dis...
With the first wave of Alzheimer's disease drugs reaching the market, investors continue to seek out the next big advance in this red-hot area of...
The Asceneuron AG from Lausanne has raised around USD 100 million to further develop its Phase II OGA inhibitor ASN51 for the treatment of Alzheimer's disease. The lead investor was Novo...
Track Asceneuron and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Asceneuron and other trending companies.